These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 38334635

  • 1. Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies.
    Mehra S, Taylor J.
    Cells; 2024 Jan 28; 13(3):. PubMed ID: 38334635
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.
    Martín-Martín L, Almeida J, Pomares H, González-Barca E, Bravo P, Giménez T, Heras C, Queizán JA, Pérez-Ceballos E, Martínez V, Alonso N, Calvo C, Álvarez R, Caballero MD, Orfao A.
    Oncotarget; 2016 Mar 01; 7(9):10174-81. PubMed ID: 26840087
    [Abstract] [Full Text] [Related]

  • 4. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jain A, Sweet K.
    J Natl Compr Canc Netw; 2023 May 01; 21(5):515-521. PubMed ID: 37156483
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
    Shumilov E, Mazzeo P, Ghandili S, Künstner A, Weidemann S, Banz Y, Ströbel P, Pollak M, Kolloch L, Beltraminelli H, Kerkhoff A, Mikesch JH, Schliemann C, Haase D, Wulf G, Legros M, Lenz G, Feldmeyer L, Pabst T, Witte H, Gebauer N, Bacher U.
    Ann Hematol; 2024 May 01; 103(5):1587-1599. PubMed ID: 38194088
    [Abstract] [Full Text] [Related]

  • 6. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y, Ursu S, Dutton N, Tanvi V, Fazal S.
    J Oncol Pharm Pract; 2021 Jun 01; 27(4):990-995. PubMed ID: 32847479
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Wilson NR, Pemmaraju N.
    Expert Opin Pharmacother; 2022 Mar 01; 23(4):431-438. PubMed ID: 35060807
    [Abstract] [Full Text] [Related]

  • 14. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
    Adimora IJ, Wilson NR, Pemmaraju N.
    Cancer; 2022 Aug 15; 128(16):3019-3026. PubMed ID: 35726525
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Pemmaraju N, Deconinck E, Mehta P, Walker I, Herling M, Garnache-Ottou F, Gabarin N, Campbell CJV, Duell J, Moshe Y, Mughal T, Mohty M, Angelucci E.
    Clin Lymphoma Myeloma Leuk; 2024 Apr 15; 24(4):e130-e137. PubMed ID: 38267355
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
    Pemmaraju N, Madanat YF, Rizzieri D, Fazal S, Rampal R, Mannis G, Wang ES, Foran J, Lane AA.
    Leuk Lymphoma; 2024 May 15; 65(5):548-559. PubMed ID: 38391126
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.